Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aminomethylbenzoic acid
- Development stage
- Unknown
- Lead developer
- Yichang Humanwell Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Aminomethylbenzoic acid, also known as PAMBA or p-aminomethylbenzoic acid, is a small molecule antifibrinolytic agent. It works by inhibiting the breakdown of fibrin clots, thereby reducing bleeding. The drug is primarily used to treat internal hemorrhage and conditions involving excessive fibrinolysis, such as chronic disseminated intravascular coagulation. Its mechanism of action involves blocking the enzymatic degradation of fibrin, which stabilizes blood clots and helps control bleeding[1][2][3][8].
- Brand names
- Aminoleic Acid Tablets
- Other names
- 4-carboxybenzylamine
02
Targets
LBS (Plasminogen lysine-binding sites)
Beyond the preview
Go deeper on aminomethylbenzoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aminomethylbenzoic acid.